Genomics of Drug Sensitivity in Cancer
Cell Line: ARH-77
Link to Cell Model Passport
Drug | Targets | Z score |
|---|---|---|
| AMG-319 | PI3K (beta sparing) | -3.22907 |
| Rapamycin | MTORC1 | -2.8059 |
| Gallibiscoquinazole | -2.61302 | |
| PAK_5339 | PAK1, PAK2 | -2.57345 |
| MK-2206 | AKT1, AKT2 | -2.40891 |
| UNC0638 | G9A, GLP | -2.3751 |
| VTP-B | -2.23168 | |
| Lenalidomide | CRBN | -2.23025 |
| KU-55933 | ATM | -2.19162 |
| Taselisib | PI3K (beta sparing) | -2.14508 |
| Pictilisib | PI3K (class 1) | -2.04398 |
| Epirubicin | Anthracycline | -1.9537 |
| Mycophenolic acid | -1.94934 | |
| Uprosertib | AKT1, AKT2, AKT3 | -1.932 |
| Motesanib | VEGFR, RET, KIT, PDGFR | -1.87745 |
| L-Oxonoreleagnine | -1.84613 | |
| AZD8186 | PI3Kalpha, PI3Kbeta | -1.82755 |
| ascorbate (vitamin C) | anti-oxidant proteins | -1.82116 |
| Cisplatin | DNA crosslinker | -1.81433 |
| MIRA-1 | TP53 | -1.77571 |
| PCI-34051 | HDAC8, HDAC6, HDAC1 | -1.77102 |
| THR-101 | Mutant RAS | -1.74973 |
| GSK-LSD1 | KDM1 | -1.74502 |
| Oxaliplatin | DNA alkylating agent | -1.69351 |
| Leflunomide | Pyrimidine synthesis inhibitor | -1.64194 |
The Genomics of Drug Sensitivity in Cancer Project is a collaboration
between the Cancer Genome Project
at the Wellcome Sanger Institute (UK)
and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.
at the Wellcome Sanger Institute (UK)
and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.
https://www.cancerrxgene.org/cellline/ARH-77/906765
Contact us | Cookies policy | Terms & Conditions.
This site is hosted by the Wellcome Sanger Institute.